Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19+ Relapse/Refractory B-ALL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchNot Yet RecruitingNCT05779930
What this trial is testing

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory+3 more
Nationwide Children's Hospital 12
Testing effectiveness (Phase 2)Study completedNCT01209286
What this trial is testing

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
B-ALL
Amgen Research (Munich) GmbH 36
Early research (Phase 1)UnknownNCT05679687
What this trial is testing

ThisCART19A Bridging to alloHSCT for R/R B-ALL

Who this might be right for
CARRefractory Acute Lymphoblastic LeukemiaRelapsed Adult ALL
The First Affiliated Hospital of Soochow University 20
Early research (Phase 1)Active Not RecruitingNCT04684563
What this trial is testing

HuCART19-IL18 in CD19+ Cancers

Who this might be right for
Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia
University of Pennsylvania 72
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Very early researchLooking for participantsNCT04227015
What this trial is testing

CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
He Huang 72
Early research (Phase 1)UnknownNCT03671460
What this trial is testing

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Tianjin Mycure Medical Technology Co., Ltd 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07020260
What this trial is testing

The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

Who this might be right for
LeukemiaLymphoma
Princess Maxima Center for Pediatric Oncology 18
Testing effectiveness (Phase 2)Study completedNCT01466179
What this trial is testing

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH 225
Testing effectiveness (Phase 2)Looking for participantsNCT03765177
What this trial is testing

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaChronic Lymphocytic Leukemia
Ottawa Hospital Research Institute 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04499573
What this trial is testing

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

Who this might be right for
B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 50
Early research (Phase 1)UnknownNCT03798509
What this trial is testing

Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

Who this might be right for
CD19-positiveAcute Lymphoblastic Leukemia
Hrain Biotechnology Co., Ltd. 18
Testing effectiveness (Phase 2)WithdrawnNCT05571540
What this trial is testing

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-ALL
Kunming Hope of Health Hospital
Testing effectiveness (Phase 2)Looking for participantsNCT06179524
What this trial is testing

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Who this might be right for
Relapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic Leukemia
Beijing Yongtai Ruike Biotechnology Company Ltd 100
Early research (Phase 1)UnknownNCT04653493
What this trial is testing

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Who this might be right for
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
Sabz Biomedicals 22
Very early researchUnknownNCT05651191
What this trial is testing

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Hrain Biotechnology Co., Ltd. 9
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Early research (Phase 1)Study completedNCT02374333
What this trial is testing

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Who this might be right for
Acute Lymphocytic LeukemiaDiffuse Large Cell Lymphoma
University of Pennsylvania 81
Early research (Phase 1)UnknownNCT03281551
What this trial is testing

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Pinze Lifetechnology Co. Ltd. 50
Early research (Phase 1)Study completedNCT04888468
What this trial is testing

Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Who this might be right for
Acute Lymphoblastic LeukemiaRelapsed Pediatric ALLRefractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd 9
Next Page